Found "Public health policy": 1,132 results
Sort by
Sort by
Relevance
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand (2013)
Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1
Summary
Purpose
There is strong evidence o
Using Financial Mechanisms to Develop a Quality and Outcomes Framework: Issues and Challenges
In the fiscal year of 2014, the National Health Security Office (NHSO) started to disburse its budget based on the Quality and Outcomes Framework (QOF). The QOF is a budget allocation mechanism that incentivizes hospitals to provide quality primary care and achieve results based on the defined indic
Cetuximab as an adjuvant therapy for metastatic colorectal cancer (mCRC): Does the high cost outweigh the benefit for saving patient’s life?
Cetuximab is provided for mCRC patients with positive KRAS wild type, and also head and neck cancer patients as indicated in the Indonesian National Drug Formulary. However, currently, it is also used for indications not specified in the National Drug Formulary.
Adding cetuximab to chemothera
Would a rotavirus vaccination program for children under 5 years be cost-effective for Bhutan?
In many countries, rotavirus vaccination is the most cost-effective way to prevent rotavirus diarrhea. With this in mind, the Essential Medicines and Technology Division (EMTD) in collaboration with Health Intervention Technology Assessment Program (HITAP), Mahidol Oxford Research Unit (MORU), and P
Early HTA: A Guide for Developing Pulmonary Tuberculosis Cost-Effective Tests Fitting the Healthcare Needs
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and represents a significant global health concern. Infectious agents can be easily spread through respiratory droplets, and TB patients face a significant risk of mortality.
The traditional sputum-based TB
The Life Saving Drug Program: Australia’s pathway to high-cost drugs
Australia developed the Life-Saving Drugs Program (LSDP) in 1995 to complement the Pharmaceutical Benefits Scheme (PBS), expanding access to high-cost drugs for rare diseases (DRD). This program, funded and administered by the Department of Health and Aged Care, permitted sponsors (often pharmaceuti
Target product profiles: opportunities and implications for health innovation development–a scoping review
Highlights
By reviewing 120 Target Product Profiles (TPPs), this study identified key aspects of TPP development processes, stakeholder involvement, common themes, major limitations, and priorities for follow-up research.
Health technologies were classified into five categories, and the pr
Examining coordinated procurement mechanisms and related regulatory policies for healthcare products in ASEAN: case studies and lesson learned
Achieving universal access to essential healthcare products remains a critical challenge across low- and middle-income countries (LMICs). While individual countries may have made notable strides in strengthening their procurement and regulatory systems, regional disparities in access, affordability,
Post-COVID Health System Strengthening
This project aims to strengthened Thai health system post COVID times and has been started since 1 April 2022 until the end of March 2023. There are five sub-projects under the grant consisting of environmental health, local governance, health financing, and digital technology.post COVID
10 / Page